The abnormal production of matrix metalloproteinases (MMPs), especially MMP-9 and MMP-2, plays a pivotal role in hypertensive disorders of pregnancy, and as such, can influence the development of preeclampsia. These alterations may result from functional genetic polymorphisms in the promoter region of MMP-9 and MMP-2 genes, which modify MMP-9 and MMP-2 expression. We investigated the association of MMP-9 polymorphism rs3918242 (-1562 C>T) and MMP-2 polymorphism rs2285053 (-735 C>T) with the risk of preeclampsia. This case-control study was conducted on 345 women with preeclampsia and 281 age-matched women with normal pregnancies from Tunisian hospitals. Genomic DNA was extracted from whole blood collected at delivery. Genotypes for -1562 C>T and -735 C>T polymorphisms were performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). An increased frequency of heterozygous MMP-9 -1562 C/T genotype carriers was observed in women with preeclampsia compared to healthy controls (p = 0.03). In contrast, the MMP-2 -735 C>T polymorphism was not significantly different regarding frequency distribution of the allele and genotype between healthy pregnant women and women with preeclampsia. Our study suggests that the MMP-9 -1562 C/T variant, associated with high MMP-9 production, could be a genetic risk factor for preeclampsia in Tunisian women.

Centre de Recherche du Centre Hospitalier de l'Université de Montréal Montréal QC H2X 0A9 Canada

Laboratory of Cytogenetics and Reproductive Biology Center of Maternity and Neonatology Monastir Fattouma Bourguiba University Teaching Hospital Monastir 5000 Tunisia

Laboratory of Histology Embryology and Cytogenetics Faculty of Medicine University of Monastir Monastir 5000 Tunisia

Laboratory of Human Genome and Multifactorial Diseases Faculty of Pharmacy of Monastir University of Monastir Monastir 5000 Tunisia

School of Kinesiology and Physical Activity Sciences Université de Montréal Montréal QC H3T 1J4 Canada

The 1st Faculty of Medicine and General University Hospital Institute of Biology and Medical Genetics Charles University 12800 Prague Czech Republic

Zobrazit více v PubMed

Kallela J., Jaaskelainen T., Kortelainen E., Heinonen S., Kajantie E., Kere J., Kivinen K., Pouta A., Laivuori H. The diagnosis of pre-eclampsia using two revised classifications in the Finnish Pre-eclampsia Consortium (FINNPEC) cohort. BMC Pregnancy Childbirth. 2016;16:221. doi: 10.1186/s12884-016-1010-0. PubMed DOI PMC

American College of Obstetricians and Gynecologists Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obs. Gynecol. 2013;122:1122–1131. PubMed

Gathiram P., Moodley J. Pre-eclampsia: Its pathogenesis and pathophysiolgy. Cardiovasc. J. Afr. 2016;27:71–78. doi: 10.5830/CVJA-2016-009. PubMed DOI PMC

Cerdeira A.S., Karumanchi S.A. Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb. Perspect. Med. 2012;2:a006585. doi: 10.1101/cshperspect.a006585. PubMed DOI PMC

Abou E.L., Hassan M., Diamandis E.P., Karumanchi S.A., Shennan A.H., Taylor R.N. Preeclampsia: An old disease with new tools for better diagnosis and risk management. Clin. Chem. 2015;61:694–698. doi: 10.1373/clinchem.2014.230565. PubMed DOI

De Vivo A., Baviera G., Giordano D., Todarello G., Corrado F., D’Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet. Gynecol. Scand. 2008;87:837–842. doi: 10.1080/00016340802253759. PubMed DOI

Su M.T., Tsai P.Y., Tsai H.L., Chen Y.C., Kuo P.L. miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9. Biofactors. 2017;43:210–219. doi: 10.1002/biof.1325. PubMed DOI

Goncalves F.M., Jacob-Ferreira A.L., Gomes V.A., Casella-Filho A., Chagas A.C., Marcaccini A.M., Gealach R.F., Tanus-Santos J.E. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin. Chim. Acta. 2009;403:173–177. doi: 10.1016/j.cca.2009.02.013. PubMed DOI

Narumiya H., Zhang Y., Fernandez-Patron C., Guilbert L.J., Davidge S.T. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens. Pregnancy. 2001;20:185–194. doi: 10.1081/PRG-100106968. PubMed DOI

Montagnana M., Lippi G., Albiero A., Scevarolli S., Salvagno G.L., Franchi M., Guidi G.C. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J. Clin. Lab. Anal. 2009;23:88–92. doi: 10.1002/jcla.20295. PubMed DOI PMC

Ulbrich S.E., Meyer S.U., Zitta K., Hiendleder S., Sinowatz F., Bauersachs S., Büttner M., Fröhlich T., Arnold G.J., Reichenbach H.-D. Bovine endometrial metallopeptidases MMP14 and MMP2 and the metallopeptidase inhibitor TIMP2 participate in maternal preparation of pregnancy. Mol. Cell. Endocrinol. 2011;332:48–57. doi: 10.1016/j.mce.2010.09.009. PubMed DOI

Gai X., Zhang Z., Liang Y., Chen Z., Yang X., Hou J., Lan X., Zheng W., Hou J., Huang M. MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Clin. Chim. Acta. 2010;411:719–724. doi: 10.1016/j.cca.2010.02.002. PubMed DOI

Lacchini R., Jacob-Ferreira A.L., Luizon M.R., Gasparini S., Ferreira-Sae M.C., Schreiber R., Nadruz W.J., Tanus-Santos J.E. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J. Hum. Hypertens. 2012;26:171–177. doi: 10.1038/jhh.2011.8. PubMed DOI

Yu Y., Wang L., Liu T., Guan H. MicroRNA-204 suppresses trophoblast-like cell invasion by targeting matrix metalloproteinase-9. Biochem. Biophys. Res. Commun. 2015;463:285–291. doi: 10.1016/j.bbrc.2015.05.052. PubMed DOI

Love C., Dave S. MicroRNA expression profiling using microarrays. Methods Mol. Biol. 2013;999:285–296. PubMed

Eleuterio N.M., Palei A.C., Rangel Machado J.S., Tanus-Santos J.E., Cavalli R.C., Sandrim V.C. Positive correlations between circulating adiponectin and MMP2 in preeclampsia pregnant. Pregnancy Hypertens. 2015;5:205–208. doi: 10.1016/j.preghy.2015.03.001. PubMed DOI

Yeh C.C., Chao K.C., Huang S.J. Innate immunity, decidual cells, and preeclampsia. Reprod. Sci. 2013;20:339–353. doi: 10.1177/1933719112450330. PubMed DOI PMC

Lou X.Y., Chen G.B., Yan L., Ma J.Z., Zhu J., Elston R.C., Li M.D. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am. J. Hum. Genet. 2007;80:1125–1137. doi: 10.1086/518312. PubMed DOI PMC

Lyall F. Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-eclampsia. Aust. N. Z. J. Obstet. Gynaecol. 2006;46:266–273. doi: 10.1111/j.1479-828X.2006.00589.x. PubMed DOI

Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., Meyer J., Cambie F., Tiret L. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579–1585. doi: 10.1161/01.CIR.0000058700.41738.12. PubMed DOI

Apple F.S., Wu A.H., Mair J., Ravkilde J., Panteghini M., Tate J., Pagani F., Christenson R.H., Mockel M., Danne O., et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin. Chem. 2005;51:810–824. doi: 10.1373/clinchem.2004.046292. PubMed DOI

Thompson M.M., Squire I.B. Matrix metalloproteinase-9 expression after myocardial infarction: Physiological or pathological? Cardiovasc. Res. 2002;54:495–498. doi: 10.1016/S0008-6363(02)00397-8. PubMed DOI

Lockwood C.J., Oner C., Uz Y.H., Kayisli U.A., Huang S.J., Buchwalder L.F., Murk W., Funai E.F., Schatz F. Matrix metalloproteinase 9 (MMP9) expression in preeclamptic decidua and MMP9 induction by tumor necrosis factor alpha and interleukin 1 beta in human first trimester decidual cells. Biol. Reprod. 2008;78:1064–1072. doi: 10.1095/biolreprod.107.063743. PubMed DOI PMC

Poon L.C., Nekrasova E., Anastassopoulos P., Livanos P., Nicolaides K.H. First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome. Prenat. Diagn. 2009;29:553–559. doi: 10.1002/pd.2234. PubMed DOI

Palei A.C., Sandrim V.C., Amaral L.M., Machado J.S., Cavalli R.C., Lacchini R., Daurte G., Tanus-Santos J.E. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharm. J. 2012;12:489–498. doi: 10.1038/tpj.2011.31. PubMed DOI

Sakowicz A., Lisowska M., Biesiada L., Rybak-Krzyszkowska M., Gach A., Sakowicz B., Grzesiak M., Huras H., Pietrucha T. Association of Maternal and Fetal Single-Nucleotide Polymorphisms in Metalloproteinase (MMP1, MMP2, MMP3, and MMP9) Genes with Preeclampsia. Dis. Markers. 2018;2018:1371425. doi: 10.1155/2018/1371425. PubMed DOI PMC

Fraser R., Walker J.J., Ekbote U.V., Martin K.L., McShane P., Orsi N.M. Interleukin-4 -590 (C>T), toll-like receptor-2 +2258 (G>A) and matrix metalloproteinase-9 -1562 (C>T) polymorphisms in pre-eclampsia. BJOG. 2008;115:1052–1056. doi: 10.1111/j.1471-0528.2008.01771.x. PubMed DOI

Rahimi Z., Rahimi Z., Aghaei A., Vaisi-Raygani A. AT2R -1332 G:A polymorphism and its interaction with AT1R 1166 A:C, ACE I/D and MMP-9 -1562 C:T polymorphisms: Risk factors for susceptibility to preeclampsia. Gene. 2014;538:176–181. doi: 10.1016/j.gene.2013.12.013. PubMed DOI

Leonardo D.P., Albuquerque D.M., Lanaro C., Baptista L.C., Cecatti J.G., Surita F.G., Parpinelli M.A., Costa F.F., Franco-Penteado C.F., Fertrin K.B., et al. Association of Nitric Oxide Synthase and Matrix Metalloprotease Single Nucleotide Polymorphisms with Preeclampsia and Its Complications. PLoS ONE. 2015;10:e0136693. PubMed PMC

Coolman M., De Maat M., Van Heerde W., Felida L., Schoormans S., Steegers E., Bertina R., De Groot C. Matrix Metalloproteinase-9 Gene -1562C/T Polymorphism Mitigates Preeclampsia. Placenta. 2007;28:709–713. doi: 10.1016/j.placenta.2006.06.017. PubMed DOI

Goncalves F.M., Martins-Oliveira A., Lacchini R., Belo V.A., Speciali J.G., Dach F., Tanus-Santos J. E Matrix metalloproteinase (MMP)-2 gene polymorphisms affect circulating MMP-2 levels in patients with migraine with aura. Gene. 2013;512:35–40. doi: 10.1016/j.gene.2012.09.109. PubMed DOI

Yu C., Zhou Y., Miao X., Xiong P., Tan W., Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res. 2004;64:7622–7628. doi: 10.1158/0008-5472.CAN-04-1521. PubMed DOI

Rahimi Z., Lotfi S., Ahmadi A., Jalilian N., Shakiba E., Vaisi-Raygani A., Rahimi Z. Matrix metalloproteinase-2 C-735T and its interaction with matrix metalloproteinase-7 A-181G polymorphism are associated with the risk of preeclampsia: Influence on total antioxidant capacity and blood pressure. J. Obs. Gynaecol. 2018;38:327–332. doi: 10.1080/01443615.2017.1354178. PubMed DOI

Palei A.C., Sandrim V.C., Amaral L.M., Machado J.S., Cavalli R.C., Duarte G., Tanus-Santos J.E. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp. Mol. Pathol. 2012;92:217–221. doi: 10.1016/j.yexmp.2012.01.008. PubMed DOI

Johnson J.D., Louis J.M. Does race or ethnicity play a role in the origin, pathophysiology, and outcomes of preeclampsia? An expert review of the literature. Am. J. Obstet. Gynecol. 2020 doi: 10.1016/j.ajog.2020.07.038. PubMed DOI

Ghosh G., Grewal J., Männistö T., Mendola P., Chen Z., Xie Y., Laughon S.K. Racial/ethnic differences in pregnancy-related hypertensive disease in nulliparous women. Ethn. Dis. 2014;24:283–289. PubMed PMC

Ben Ali Gannoun M., Bourrelly S., Raguema N., Zitouni H., Nouvellon E., Maleh W., Chemilia A.B., Elfeleh R., Almawi W., Mahjoub T., et al. Placental growth factor and vascular endothelial growth factor serum levels in Tunisian Arab women with suspected preeclampsia. Cytokine. 2016;79:1–6. doi: 10.1016/j.cyto.2015.12.005. PubMed DOI

Ben Ali M., Messaoudi S., Ezzine H., Mahjoub T. Contribution of eNOS variants to the genetic susceptibility of coronary artery disease in a Tunisian population. Genet. Test. Mol. Biomark. 2015;19:203–208. doi: 10.1089/gtmb.2014.0261. PubMed DOI

American College of Obstetricians and Gynecologists Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obs. Gynecol. 2020;135:e237–e260. doi: 10.1097/AOG.0000000000003891. PubMed DOI

Raguema N., Zitouni H., Ben Ali Gannoun M., Benletaifa D., Almawi W.Y., Mahjoub T., Lavoie J.L. FAS A-670G and Fas ligand IVS2nt A 124G polymorphisms are significantly increased in women with pre-eclampsia and may contribute to HELLP syndrome: A case-controlled study. BJOG. 2018;125:1758–1764. doi: 10.1111/1471-0528.15412. PubMed DOI

Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215. doi: 10.1093/nar/16.3.1215. PubMed DOI PMC

Wolf C., Rentsch J., Hubner P. PCR-RFLP analysis of mitochondrial DNA: A reliable method for species identification. J. Agric. Food Chem. 1999;47:1350–1355. doi: 10.1021/jf9808426. PubMed DOI

Demir-Weusten A.Y., Seval Y., Kaufmann P., Demir R., Yucel G., Huppertz B. Matrix metalloproteinases-2, -3 and -9 in human term placenta. Acta Histochem. 2007;109:403–412. doi: 10.1016/j.acthis.2007.04.001. PubMed DOI

Chen J., Khalil R.A. Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia. Prog. Mol. Biol. Transl. Sci. 2017;148:87–165. PubMed PMC

Rahimi Z., Rahimi Z., Shahsavandi M.O., Bidoki K., Rezaei M. MMP-9 (-1562 C:T) polymorphism as a biomarker of susceptibility to severe pre-eclampsia. Biomark. Med. 2013;7:93–98. doi: 10.2217/bmm.12.95. PubMed DOI

Medley T.L., Cole T.J., Dart A.M., Gatzka C.D., Kingwell B.A. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Artern. Thromb. Vasc. Biol. 2004;24:1479–1484. doi: 10.1161/01.ATV.0000135656.49158.95. PubMed DOI